His primary areas of investigation include Prostate cancer, Pathology, Prostate, PCA3 and Cancer. Jack A. Schalken interconnects Cancer research, Gynecology and Oncology in the investigation of issues within Prostate cancer. The various areas that Jack A. Schalken examines in his Pathology study include Bladder cancer, Cellular differentiation and Antigen.
His work deals with themes such as Cancer cell, Biopsy, Hyperplasia and Urology, which intersect with Prostate. His PCA3 study incorporates themes from Biomarker, Urine, Urinary system and Rectal examination. The concepts of his Cancer study are interwoven with issues in Cadherin and Telomerase, Telomerase reverse transcriptase.
His primary scientific interests are in Prostate cancer, Internal medicine, Pathology, Oncology and Cancer research. His Prostate cancer study integrates concerns from other disciplines, such as Biomarker, Biopsy and Prostate. His Prostate research incorporates themes from Cellular differentiation, Hyperplasia and Adenocarcinoma.
His study in Pathology is interdisciplinary in nature, drawing from both Bladder cancer, Cadherin and Urinary bladder, Urothelium. His Cancer research study also includes
Jack A. Schalken spends much of his time researching Prostate cancer, Internal medicine, Oncology, Cancer research and Prostate. His research integrates issues of Biomarker, Biopsy and Urine in his study of Prostate cancer. His Oncology research includes themes of Prostate-specific antigen, Liquid biopsy and Prospective cohort study.
His Cancer research research is multidisciplinary, incorporating elements of Cancer cell, Cancer, Transcriptome, Castration resistant and Androgen receptor. In his research on the topic of Prostate, Gene expression profiling, Real-time polymerase chain reaction and Urothelium is strongly related with Pathology. His biological study spans a wide range of topics, including Gynecology and Rectal examination.
Jack A. Schalken mainly focuses on Prostate cancer, Internal medicine, Oncology, Biomarker and PCA3. Jack A. Schalken has included themes like Prostate and Gynecology in his Prostate cancer study. His Internal medicine study which covers Endocrinology that intersects with Receptor.
His Oncology study combines topics in areas such as Bladder cancer, Cancer, Liquid biopsy and Prospective cohort study. His research in Biomarker intersects with topics in DNA microarray, Rectal examination and Pathology. In general Pathology study, his work on Epithelium often relates to the realm of Oncotype DX, thereby connecting several areas of interest.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
DD3::A New Prostate-specific Gene, Highly Overexpressed in Prostate Cancer
M.J.G. Bussemakers;A. van Bokhoven;G.W.C.T. Verhaegh;F.P. Smit.
Cancer Research (1999)
DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer
Daphne Hessels;Jacqueline M.T. Klein Gunnewiek;Inge van Oort;Herbert F.M. Karthaus.
European Urology (2003)
Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.
Umbas R;Schalken Ja;Aalders Tw;Carter Bs.
Cancer Research (1992)
DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.
Jacques B de Kok;Gerald W Verhaegh;Rian W Roelofs;Daphne Hessels.
Cancer Research (2002)
Decreased E-Cadherin Expression Is Associated with Poor Prognosis in Patients with Prostate Cancer
R. Umbas;W. B. Isaacs;P. P. Bringuier;H. E. Schaafsma.
Cancer Research (1994)
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.
Thorunn Rafnar;Patrick Sulem;Simon N Stacey;Frank Geller.
Nature Genetics (2009)
Allelic loss of chromosomes 16q and 10q in human prostate cancer.
B S Carter;C M Ewing;W S Ward;B F Treiger.
Proceedings of the National Academy of Sciences of the United States of America (1990)
Cadherin Switching in Human Prostate Cancer Progression
K. Tomita;A. Van Bokhoven;G. J. L. H. Van Leenders;E. T. G. Ruijter.
Cancer Research (2000)
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
Alexander Haese;Alexandre de la Taille;Hendrik van Poppel;Michael Marberger.
European Urology (2008)
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers
Vinata B. Lokeshwar;Tomonori Habuchi;H. Barton Grossman;William M. Murphy.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: